EASL Updates: Intercept Says Biomarker Data Bolster OCA’s Case For Fibrosis Benefit
Executive Summary
Intercept and Axcella provide updated data on their NASH programs at the International Liver Conference, while CymaBay offers the full dataset for seladelpar in PBC.